Evidence map›Paper›PMID 32371374›Full record

ArticleiScience2020

An Unsupervised Strategy for Identifying Epithelial-Mesenchymal Transition State Metrics in Breast Cancer and Melanoma.

David J Klinke, Arezo Torang

Abstract read
In one paragraph

Article in iScience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

David J KlinkeDepartment of Chemical and Biomedical Engineering, West Virginia University, Morgantown, WV, USA; Department of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, WV, USA; WVU Cancer Institute, West Virginia University, Morgantown, WV, USA. Electronic address: david.klinke@mail.wvu.edu.
Arezo TorangAmsterdam UMC, University of Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam, the Netherlands; Oncode Institute, UMC, University of Amsterdam, Amsterdam, the Netherlands.

Funding

Integrative systems approach to identify local oncogenic modulation of the IL12 axisR01CA193473 · NCI · WEST VIRGINIA UNIVERSITY · PI KLINKE, DAVID JOHN · 2016 to 2020
$1.7M
NCI NIH HHS R01 CA193473
6 · The paper itself

Abstract

Digital cytometry aims to identify different cell types in the tumor microenvironment, with the current focus on immune cells. Yet, identifying how changes in tumor cell phenotype, such as the epithelial-mesenchymal transition, influence the immune contexture is emerging as an important question. To extend digital cytometry, we developed an unsupervised feature extraction and selection strategy to capture functional plasticity tailored to breast cancer and melanoma separately. Specifically, principal component analysis coupled with resampling helped develop gene expression-based state metrics that characterize differentiation within an epithelial to mesenchymal-like state space and independently correlate with metastatic potential. First developed using cell lines, the orthogonal state metrics were refined to exclude the contributions of normal fibroblasts and provide tissue-level state estimates using bulk tissue RNA-seq measures. The resulting metrics for differentiation state aim to inform a more holistic view of how the malignant cell phenotype influences the immune contexture within the tumor microenvironment.

Indexed as

BioinformaticsCancerStem Cells Research

Identifiers

PMID32371374
PMCPMC7200934

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.